NY-ESTÉE-LAUDER
11.5.2021 13:02:09 CEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE:EL) announced today that Meridith Webster will join the company in the newly-created role of Executive Vice President, Global Communications and Public Affairs , effective May 17, 2021. Meridith will report jointly to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer. She will also join The Estée Lauder Companies Inc.’s (“ELC”) Executive Leadership Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005345/en/
Meridith will succeed Alexandra (Alex) Trower as head of Global Communications and Maria Cristina (MC) González Noguera as head of Global Public Affairs. Her appointment follows the news that Alex has made the decision to retire in June after an esteemed career at the company, and that MC was recently tapped for the role of EVP and Chief Communications and Public Affairs Officer at Popular Inc., the Puerto Rico-based global financial services conglomerate.
“Our world-class Global Communications and Public Affairs teams have consistently advanced ahead of the curve against the backdrop of an increasingly complex and rapidly-changing global landscape,” said Fabrizio Freda . “Meridith’s appointment will continue to enable and enhance our delivery of thoughtful, effective communications to our valued global stakeholders as she leads these talented teams to new heights.”
“Meridith’s deep public and private sector experience, coupled with her core values and leadership style, make her uniquely suited to step into this role now,” said William P. Lauder . “I am so proud of the incredible work of our Global Communications and Public Affairs teams and I know they will be in great hands under Meridith’s leadership as she joins our ELC family.”
In this new role, Meridith will lead ELC’s global communications and public affairs strategic agendas to advance and protect its business interests and corporate reputation globally, and strengthen relationships to drive value for key stakeholders. She will serve as a strategic advisor to the ELC’s Executive Leadership Team, the Board of Directors and the Lauder Family on a variety of critical topics.
Meridith will oversee ELC’s Global Communications and Public Affairs teams, elevating the impact of these important functions across the business. She will lead the strategy and delivery of holistic, integrated global communications to advance ELC’s corporate reputation and winning business narrative, while building brand equity and strengthening the platforms that resonate with key audiences internally and externally. She will also lead the global public affairs and stakeholder engagement strategy to further advance ELC’s business goals, build reputation capital and proactively mitigate issues.
Meridith’s deep government experience includes tenures under multiple U.S. presidential administrations. Meridith joins ELC from the Biden White House, where she served as Special Assistant to the President and Chief of Staff to the Domestic Policy Council. At the Obama White House, she served as Senior Advisor to two White House Chiefs of Staff, Rahm Emanuel and Pete Rouse. She also served as Deputy Chief of Staff to Susan Rice, then the U.S. Ambassador to the United Nations. Meridith started her career working at the Clinton White House and the U.S. State Department before earning her J.D. Degree at Georgetown University Law Center.
Prior to serving in the Biden Administration, she served as Vox Media’s first-ever Chief Communications Officer, overseeing strategic and crisis communications and media relations across a growing modern media company, including editorial networks and advertising, studios, and podcasting. She also previously led the Public Affairs practice at Emerson Collective and served as Global Head of Public Affairs at Bloomberg L.P. and Bloomberg Philanthropies where she managed the expansion of the business and established public affairs and communications functions in Washington, New York and globally.
“I am thrilled to be joining The Estée Lauder Companies. Alex and MC each have done a terrific job leading the company’s Global Communications and Public Affairs functions and positioning these talented teams as strategic business partners,” said Meridith Webster . “It is an honor to step into this new role and I am excited to continue building on the successes of these teams in a rapidly-evolving space. I look forward to partnering with Fabrizio, William and the entire Executive Leadership Team to drive the overall success and continued growth of ELC.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
